bioTheranostics

Biotheranostics, acquired by Hologic in February 2021, specializes in proprietary genomic assays aimed at enhancing personalized disease management in oncology. The company is particularly recognized for its offerings, including the Breast Cancer Index and CancerTYPE ID, which support clinicians in making informed treatment decisions for patients with breast and metastatic cancers.

The Breast Cancer Index is distinguished as the only genomic test endorsed by the ASCO Clinical Practice Guideline and the NCCN Clinical Practice Guidelines in Oncology for predicting the benefit of extended endocrine therapy in HR early-stage breast cancer. Meanwhile, CancerTYPE ID is celebrated as the most validated gene expression-based assay for accurately identifying tumor type and subtype in metastatic cancer patients with ambiguous diagnoses.

Generated from the website